Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 6.94Mに達しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 6.94Mです。
割安
同社の最新のPEは-9.91で、過去3年間の水準と比較して安値圏にあります。
機関投資家の買い増し
最新の機関投資家の保有株数は116.25M株で、前四半期比で11.97%増加しています。
ETHSXが保有
スター投資家ETHSXは本銘柄を35.76K株保有しています。
市場活動が活発
同社への投資家の関心が高まっており、20日間の売買回転率は0.36です。